Teva Might Have Broken Competition Rules, EU Watchdog Says -- Update
10 Octobre 2022 - 12:39PM
Dow Jones News
By Cristina Roca and Pierre Bertrand
The European Union has informed Teva Pharmaceutical Industries
Ltd. of its preliminary view that the company breached antitrust
rules to shield its multiple sclerosis drug Copaxone from
competition.
The bloc's executive arm, the European Commission, said Monday
that the Israeli-based pharmaceutical company could have
artificially extended its exclusivity on Copaxone by hindering
glatiramer acetate competitors from entering the market.
Teva said it will defend itself vigorously against the
claims.
"While we will first seek to persuade the EC that their
preliminary view is incorrect, we are also prepared if needed to
contest any allegations resulting from the EC's investigation using
all the legal and other procedural rights at our disposal," it
said. It warned the matter could take years to resolve.
Teva had a basic patent on glatiramer acetate, Copaxone's active
ingredient, until 2015, the Commission said.
"Our concern is that Teva may have misused the patent system to
shield itself from competition," EU Commission Executive
Vice-President Margrethe Vestager, said in a statement. "It may
have spread misleading information to discredit its closest
competitor, to the detriment of patients and public health systems
across the EU," she added.
If the alleged violations are confirmed, Teva could be fined,
the Commission said.
Write to Cristina Roca at cristina.roca@wsj.com and Pierre
Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
October 10, 2022 06:24 ET (10:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024